Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors

Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors Publisher Pubmed

Kassaian SE¹ ; Fathi Y¹ ; Lotfitokaldany M² ; Salarifar M¹ ; Alidoosti M¹ ; Hajizeinali AM¹ ; Aghajani H¹ ; Amirzadegan A¹ ; Nozari Y¹ ; Mortazavi SH¹ ; Jalali A¹ ; Saroukhani S¹

Show Affiliations

1. Department of Interventional Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, PO Box: 1411713138, Tehran, Iran
2. Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Critical Pathways in Cardiology Published:2016

Abstract

Objective: The aim of this study is to compare intracoronary (IC) bolus only with IC bolus plus maintenance intravenous (IV) infusion of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors with respect to 1-year major adverse cardiac events including mortality, nonfatal myocardial infarction, revascularization, and bleeding events after primary percutaneous coronary intervention (PCI). Methods: This is an observational study of 233 consecutive patients who presented with ST-elevation myocardial infarction and underwent primary PCI between April 2009 and December 2012. Patients were grouped into (1) patients who received IC bolus only (n = 102) and (2) patients who received IC bolus plus maintenance IV infusion of GP IIb/IIIa inhibitors (n = 131). In-hospital post procedural myocardial infarction occurred in 4 (1.7 %) of patients. Results: Mortality occurred in one patient who was treated with IV infusion. Major bleeding occurred in only 5 patients, among whom 4 patients had received GP IIb/IIIa inhibitors IV infusion. However, the difference was not statistically significant (P = 0.389). Conclusion: Both univariate analysis and the adjusted model for the potential confounders revealed no significant association between the way of GP IIb/IIIa inhibitors administration and 1-year major adverse cardiac events. Our findings suggested that IV infusion of GP IIb/IIIa inhibitors after the bolus dose is not associated with better 1-year outcome after adjustment for confounding variables. Moreover, IV infusion may increase the risk of major bleedings after primary PCI. This finding implies that the need for IV infusion of GP IIb/IIIa inhibitors in patients undergoing primary PCI is under question. © Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved.

Style	Citing Format
MLA	Kassaian SE, et al.. "Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors." Critical Pathways in Cardiology, vol. 15, no. 3, 2016, pp. 89-94.
APA	Kassaian SE, Fathi Y, Lotfitokaldany M, Salarifar M, Alidoosti M, Hajizeinali AM, Aghajani H, Amirzadegan A, Nozari Y, Mortazavi SH, Jalali A, Saroukhani S (2016). Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors. Critical Pathways in Cardiology, 15(3), 89-94.
Chicago	Kassaian SE, Fathi Y, Lotfitokaldany M, Salarifar M, Alidoosti M, Hajizeinali AM, Aghajani H, et al.. "Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors." Critical Pathways in Cardiology 15, no. 3 (2016): 89-94.
Harvard	Kassaian SE et al. (2016) 'Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors', Critical Pathways in Cardiology, 15(3), pp. 89-94.
Vancouver	Kassaian SE, Fathi Y, Lotfitokaldany M, Salarifar M, Alidoosti M, Hajizeinali AM, et al.. Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors. Critical Pathways in Cardiology. 2016;15(3):89-94.
BibTex	@article{ author = {Kassaian SE and Fathi Y and Lotfitokaldany M and Salarifar M and Alidoosti M and Hajizeinali AM and Aghajani H and Amirzadegan A and Nozari Y and Mortazavi SH and Jalali A and Saroukhani S}, title = {Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors}, journal = {Critical Pathways in Cardiology}, volume = {15}, number = {3}, pages = {89-94}, year = {2016} }
RIS	TY - JOUR AU - Kassaian SE AU - Fathi Y AU - Lotfitokaldany M AU - Salarifar M AU - Alidoosti M AU - Hajizeinali AM AU - Aghajani H AU - Amirzadegan A AU - Nozari Y AU - Mortazavi SH AU - Jalali A AU - Saroukhani S TI - Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors JO - Critical Pathways in Cardiology VL - 15 IS - 3 SP - 89 EP - 94 PY - 2016 ER -

Style

Citing Format

MLA

Kassaian SE, et al.. "Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors." Critical Pathways in Cardiology, vol. 15, no. 3, 2016, pp. 89-94.

APA

Kassaian SE, Fathi Y, Lotfitokaldany M, Salarifar M, Alidoosti M, Hajizeinali AM, Aghajani H, Amirzadegan A, Nozari Y, Mortazavi SH, Jalali A, Saroukhani S (2016). Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors. Critical Pathways in Cardiology, 15(3), 89-94.

Chicago

Kassaian SE, Fathi Y, Lotfitokaldany M, Salarifar M, Alidoosti M, Hajizeinali AM, Aghajani H, et al.. "Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors." Critical Pathways in Cardiology 15, no. 3 (2016): 89-94.

Harvard

Kassaian SE et al. (2016) 'Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors', Critical Pathways in Cardiology, 15(3), pp. 89-94.

Vancouver

Kassaian SE, Fathi Y, Lotfitokaldany M, Salarifar M, Alidoosti M, Hajizeinali AM, et al.. Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors. Critical Pathways in Cardiology. 2016;15(3):89-94.

BibTex

@article{ author = {Kassaian SE and Fathi Y and Lotfitokaldany M and Salarifar M and Alidoosti M and Hajizeinali AM and Aghajani H and Amirzadegan A and Nozari Y and Mortazavi SH and Jalali A and Saroukhani S}, title = {Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors}, journal = {Critical Pathways in Cardiology}, volume = {15}, number = {3}, pages = {89-94}, year = {2016} }

RIS

TY - JOUR
AU - Kassaian SE
AU - Fathi Y
AU - Lotfitokaldany M
AU - Salarifar M
AU - Alidoosti M
AU - Hajizeinali AM
AU - Aghajani H
AU - Amirzadegan A
AU - Nozari Y
AU - Mortazavi SH
AU - Jalali A
AU - Saroukhani S
TI - Comparison of 1-Year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein Iib/Iiia Inhibitors
JO - Critical Pathways in Cardiology
VL - 15
IS - 3
SP - 89
EP - 94
PY - 2016
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract